Associated Papers
Preclinical assessment of combination therapy of EGFR tyrosine kinase inhibitors in a highly heterogeneous tumor model.
Ikeuchi H et al.
Oncogene, 2022
35304574 (PubMed )
Supplement: 41388_2022_2263_MOESM5_ESM.xlsx › Supplementary_Table_4
Evolution of oncogenic signatures of mutation hotspots in tyrosine kinases supports the atavistic hypothesis of cancer.
Chen W et al.
Scientific Reports, 2018
29844492 (PubMed )
Supplement: 41598_2018_26653_MOESM2_ESM.xlsx › Dataset_S1
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency.
Sun C et al.
Cancer Cell, 2018
Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR et al.
Pathology Oncology Research : Por, 2015
EGFR mutational status in a large series of Caucasian European NSCLC patients: data from daily practice.
Gahr S et al.
British Journal of Cancer, 2013
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.
Yeh P et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2013
Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.
Yu J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2009
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Wu SG et al.
The Oncologist, 2008
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC.
Kalikaki A et al.
British Journal of Cancer, 2008
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
Pallis AG et al.
British Journal of Cancer, 2007
Select a paper to view details